Johnson & Johnson (NY:JNJ)

256.03 -2.63 (-1.02%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

99 100 Next >

S&P 500 Eyes 7,000 Milestone: Technical Breakout Sets the Stage for a High-Stakes 2026

December 31, 2025

As the final closing bell of 2025 rings on Wall Street, the S&P 500 (SPX) stands on the precipice of history. After a year defined by a "triple-tailwind" of aggressive Federal Reserve easing, a...

Via MarketMinute

Palantir Shares Retreat to $180.80 as Hawkish Fed Minutes and Institutional Rebalancing Cool Year-End Rally

December 30, 2025

Palantir Technologies (NYSE: PLTR) saw its shares slide in after-hours trading on Tuesday, December 30, 2025, as a combination of hawkish signals from the Federal Reserve and aggressive year-end...

Via MarketMinute

Topics Artificial Intelligence Economy

The Trillion-Dollar Shuffle: How Year-End Institutional Rebalancing is Fueling Late-December Volatility

December 30, 2025

As the final trading days of 2025 unfold, the financial markets are witnessing a phenomenon that analysts have dubbed the "Great Rebalancing." While the S&P 500 is poised to finish the year with...

Via MarketMinute

Topics Artificial Intelligence Bonds ETFs

The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal

December 30, 2025

As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Hunterbrook Capital Bets Big on Achieve Life Sciences: Why a 'Toxic Tree' Could Disrupt the Multi-Billion Dollar Smoking Cessation Market

December 30, 2025

In a move that has sent ripples through the biotech sector on the final trading days of the year, Hunterbrook Capital announced a significant bullish position in Achieve Life Sciences (NASDAQ:ACHV)...

Via MarketMinute

Topics Product Recall

The S&P 500 Seesaw: Analyzing IVV’s Year-End Turbulence After a Record-Breaking 2025

December 30, 2025

The financial markets are closing out 2025 in a state of high-octane paradox. The iShares Core S&P 500 ETF (NYSE Arca: IVV), the massive exchange-traded fund that serves as a cornerstone for millions...

Via MarketMinute

Topics ETFs Economy Retirement

Wall Street Stumbles at the Finish Line: S&P 500 and Nasdaq Fight to Break 3-Day Slide Amid Year-End Rebalancing

December 30, 2025

As the 2025 trading calendar winds down to its final hours, the festive atmosphere on Wall Street has been replaced by a clinical, high-stakes battle for technical support. On this Tuesday, December...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

The 2026 Income Fortress: Why Big Pharma is the Defensive Play of the New Year

December 30, 2025

As the sun sets on 2025, investors are increasingly pivoting toward the pharmaceutical sector, seeking a "defensive income fortress" to weather potential macroeconomic volatility in 2026. The...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever ↗

December 30, 2025

Investors seeking reliable dividends will find that this trio of healthcare stocks offers an exciting combination of safety, growth, and income.

Via The Motley Fool

Topics Economy Intellectual Property

Could These 3 "Recession-Proof" Dividend Stocks Surge 100% by 2031? ↗

December 29, 2025

All three are buys, but for different reasons.

Via The Motley Fool

Topics Artificial Intelligence Economy Intellectual Property

The Santa Claus Stumble: Markets Pivot from Record Highs to Year-End Consolidation

December 29, 2025

As the final trading days of 2025 unfold, the festive exuberance that propelled Wall Street to the brink of historic milestones is beginning to cool. After a blistering mid-December surge that saw the...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

The Price of Prosperity: Navigating the S&P 500’s Historic Valuation Peak as 2026 Dawns

December 29, 2025

As the final trading days of 2025 draw to a close, the financial world finds itself standing on a high-altitude plateau that few predicted and many fear. The S&P 500 (INDEXSP: .INX) enters 2026 trading...

Via MarketMinute

Topics Artificial Intelligence Bonds Earnings

Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

December 29, 2025

From Johnson & Johnson

Via Business Wire

Blue-Chip Bull Run: Dow Jones Eyes 50,000 Milestone Amidst 2026 Technical Pivot

December 26, 2025

As the final bells of 2025 ring across the floor of the New York Stock Exchange, the Dow Jones Industrial Average (DJI) stands at a historic crossroads. After a year defined by a resilient "soft...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

The 2025 Growth Postgame: Analyzing the AI Supercycle and Preparing for the 2026 'Agentic' Pivot

December 26, 2025

As the final trading days of 2025 wind down, the global investment community has entered a period of intense reflection. This year’s market was defined by a breathtaking "tale of two halves," where...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

Johnson & Johnson Terminates Experimental Eczema Drug Study After It Fails To Show Benefit ↗

December 26, 2025

The company said that the drug did not achieve the “high-bar””efficacy targets in a planned interim analysis.

Via Stocktwits

Johnson & Johnson Halts Atopic Dermatitis Study After Interim Analysis Miss ↗

December 26, 2025

Johnson & Johnson's Phase 2b study for atopic dermatitis did not meet high-bar efficacy and was terminated early.

Via Benzinga

Baxter International (BAX) in 2025: A Deep Dive into the Transformation of a MedTech Giant

December 26, 2025

As of December 26, 2025, Baxter International Inc. (NYSE: BAX) stands at a pivotal crossroads in its nearly century-long history. Long considered a defensive "blue-chip" staple of the healthcare...

Via PredictStreet

Topics Economy Emissions Product Recall

Pfizer’s 2026 Outlook Misses the Mark as Post-Pandemic Hangover and Patent Cliff Loom

December 25, 2025

NEW YORK — On December 16, 2025, Pfizer (NYSE:PFE) issued a conservative financial outlook for the 2026 fiscal year, falling short of Wall Street’s expectations and signaling a prolonged period of...

Via MarketMinute

Topics Economy Intellectual Property

Barking Back: Why the 'Dogs of the Dow' 4-Stock Play is the Contrarian Bet for 2026

December 25, 2025

As investors close the books on 2025, a year defined by the continued—yet tiring—dominance of artificial intelligence and mega-cap technology, the financial community is turning its gaze toward a...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

This Dividend ETF Could Quietly Make You a Multimillionaire Over Time ↗

December 24, 2025

This ETF invests in stocks with proven wealth-creating capabilities.

Via The Motley Fool

Topics ETFs

Top 5 US Healthcare Stocks By Market Value ↗

December 24, 2025

Weight-loss drugs, drug-pricing reforms, and legal challenges have reshaped the U.S. healthcare landscape in 2025.

Via Stocktwits

Legal Seismic Shift: Johnson & Johnson Faces Record $1.5 Billion Talc Verdict as Bankruptcy Strategy Collapses

December 23, 2025

In a landmark ruling that has sent shockwaves through the corporate legal landscape, a Baltimore jury has ordered Johnson & Johnson (NYSE: JNJ) to pay a staggering $1.56 billion to a single plaintiff....

Via MarketMinute

Topics Bankruptcy Bonds Lawsuit

Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗

December 23, 2025

Via Stocktwits

Topics Government

The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025

December 23, 2025

After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The...

Via MarketMinute

Topics Economy

The Dividend King Buy-and-Hold Strategy That Can Surge 100% in 10 Years ↗

December 23, 2025

These low-risk dividend stocks have the potential to produce a more than 100% total return over the next decade.

Via The Motley Fool

Johnson & Johnson Hit With Record $1.5 Billion US Verdict Over Talc Cancer Claim ↗

December 23, 2025

Baltimore jury awards $1.5 billion against Johnson & Johnson in record talc-asbestos mesothelioma verdict; company plans to appeal.

Via Benzinga

The Great Consolidation: Why 2026 is Set to Become the 'Year of the Mega-Deal'

December 22, 2025

As the curtain closes on 2025, the global financial landscape is witnessing a seismic shift in corporate strategy. After two years of "wait-and-see" posturing dictated by high interest rates and...

Via MarketMinute

Topics Artificial Intelligence Economy Government

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Via MarketMinute

Topics ETFs Economy Intellectual Property

What to Expect From Johnson & Johnson’s Next Quarterly Earnings Report

December 22, 2025

Investor interest is building ahead of Johnson & Johnson’s Q4 earnings, backed by positive analyst sentiment.

Via Barchart.com

Topics ETFs

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.